Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential non-cross-resistant chemotherapy versus standard R-CHOP for intermediate- and high-risk diffuse large B-cell lymphoma
ChiCTR1800018720Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 6 more in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 5-year disease-free survival. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR1800018720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018720.